Charles Butts

11.4k total citations · 1 hit paper
96 papers, 5.3k citations indexed

About

Charles Butts is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Charles Butts has authored 96 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Charles Butts's work include Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (28 papers) and Lung Cancer Diagnosis and Treatment (26 papers). Charles Butts is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (28 papers) and Lung Cancer Diagnosis and Treatment (26 papers). Charles Butts collaborates with scholars based in Canada, United States and Italy. Charles Butts's co-authors include Frances A. Shepherd, Randeep Sangha, Tony Reiman, Yvon Cormier, Glenwood Goss, Michael B. Sawyer, Peter Ellis, Keyue Ding, Andrew Scarfe and Vickie E. Baracos and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Charles Butts

93 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

2015 330 citations Massimo Di Maïo, Ciro Gallo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Butts Canada	32	3.5k	2.6k	1.1k	778	450	96	5.3k
Glenwood Goss Canada	36	3.6k 1.0×	3.5k 1.3×	1.7k 1.5×	560 0.7×	172 0.4×	129	6.3k
Jyoti D. Patel United States	38	3.9k 1.1×	3.4k 1.3×	1.4k 1.3×	495 0.6×	159 0.4×	230	6.1k
Jean‐Philippe Spano France	38	3.0k 0.9×	1.2k 0.5×	1.1k 1.1×	501 0.6×	155 0.3×	190	5.1k
Jean‐Marie Michot France	37	3.6k 1.0×	937 0.4×	1.1k 1.0×	1.2k 1.6×	212 0.5×	199	5.7k
Scott A. Laurie Canada	36	4.3k 1.2×	3.3k 1.3×	1.2k 1.1×	622 0.8×	174 0.4×	163	6.3k
Keun‐Wook Lee South Korea	41	4.0k 1.1×	3.3k 1.3×	1.3k 1.2×	592 0.8×	208 0.5×	265	7.3k
Siow Ming Lee United Kingdom	38	2.4k 0.7×	2.0k 0.8×	1.6k 1.5×	417 0.5×	142 0.3×	171	4.9k
Guido Francini Italy	28	4.1k 1.2×	1.3k 0.5×	604 0.6×	671 0.9×	126 0.3×	113	5.3k
Umberto Basso Italy	35	2.1k 0.6×	1.7k 0.7×	1.0k 0.9×	272 0.3×	498 1.1×	236	4.7k
Philip Bonomi United States	42	4.9k 1.4×	4.4k 1.7×	2.1k 2.0×	343 0.4×	175 0.4×	241	8.0k

Countries citing papers authored by Charles Butts

Since Specialization

Citations

This map shows the geographic impact of Charles Butts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Butts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Butts more than expected).

Fields of papers citing papers by Charles Butts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Butts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Butts. The network helps show where Charles Butts may publish in the future.

Co-authorship network of co-authors of Charles Butts

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Butts. A scholar is included among the top collaborators of Charles Butts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Butts. Charles Butts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Steuer, Conor, Opeyemi A. Jegede, Suzanne E. Dahlberg, et al.. (2021). Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. Journal of Thoracic Oncology. 16(6). 960–967. 8 indexed citations

Kazemi‐Bajestani, Seyyed Mohammad Reza, Harald Becher, Charles Butts, et al.. (2018). Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials. Supportive Care in Cancer. 27(4). 1551–1561. 8 indexed citations

Cabanero, Michael, Randeep Sangha, Brandon S. Sheffield, et al.. (2017). Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective. Current Oncology. 24(2). 111–119. 21 indexed citations

Font, E. Felip, Scott Gettinger, Scott Antonia, et al.. (2017). Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v462–v462. 22 indexed citations

Davis, F., et al.. (2016). Waiting Time Intervals for Non-small Cell Lung Cancer Diagnosis and Treatment in Alberta: Quantification of Intervals and Identification of Risk Factors Associated with Delays. Clinical Oncology. 28(12). 750–759. 21 indexed citations

Maïo, Massimo Di, Ciro Gallo, Natasha B. Leighl, et al.. (2015). Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. Journal of Clinical Oncology. 33(8). 910–915. 330 indexed citations breakdown →

Chu, Michael P., Sunita Ghosh, Carole Chambers, et al.. (2014). Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 16(1). 33–39. 80 indexed citations

Butts, Charles, Suzanne Kamel‐Reid, Gerald Batist, et al.. (2013). Benefits, Issues, and Recommendations for Personalized Medicine in Oncology in Canada. Current Oncology. 20(5). 475–483. 22 indexed citations

Groen, Harry J.M., Mark A. Socinski, Francesco Grossi, et al.. (2013). A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Annals of Oncology. 24(9). 2382–2389. 47 indexed citations

10.

Butts, Charles, et al.. (2011). Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer. Annals of Oncology. 22(8). 1902–1909. 12 indexed citations

11.

Winget, Marcy, et al.. (2010). Uptake and tolerance of adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada. Lung Cancer. 72(1). 52–58. 6 indexed citations

12.

Thatcher, Nick, Thomas J. Lynch, Charles Butts, et al.. (2009). Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials. Journal of Thoracic Oncology. 4(9). 15 indexed citations

13.

Bathe, Oliver F., Scott Ernst, Francis Sutherland, et al.. (2009). A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer. 9(1). 156–156. 29 indexed citations

14.

Winget, Marcy, Jennifer Stanger, Zhiwei Gao, & Charles Butts. (2009). Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada. Journal of Thoracic Oncology. 4(5). 629–634. 17 indexed citations

15.

Rothenberg, Mace L., John V. Cox, Charles Butts, et al.. (2008). Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Annals of Oncology. 19(10). 1720–1726. 156 indexed citations

16.

Butts, Charles, David Bodkin, Edward L. Middleman, et al.. (2007). Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(36). 5777–5784. 160 indexed citations

17.

Butts, Charles, Andrew W. Maksymiuk, Glenwood Goss, et al.. (2007). B1-01: A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. Journal of Thoracic Oncology. 2(8). S332–S333. 36 indexed citations

18.

Yee, Don, Ross Halperin, John Hanson, et al.. (2006). Phase I study of hypofractionated dose-escalated thoracic radiotherapy for limited-stage small-cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 65(2). 466–473. 11 indexed citations

19.

Twelves, Chris, Charles Butts, Jim Cassidy, et al.. (2005). Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study. Clinical Colorectal Cancer. 5(2). 101–107. 44 indexed citations

20.

Bathe, Oliver F., Scot Dowden, Francis Sutherland, et al.. (2004). Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 4(1). 32–32. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact